New review shows statins remain first-line therapy in MASLD, while PCSK9 inhibitors offer potential but require more evidence. Learn more about evolving treatment guidance.

FDA review finds increased risk of muscle damage, kidney failure. June 9, 2011 — -- The U.S. Food and Drug Administration has recommended limiting high doses of a widely prescribed ...

The FDA has completed its review of the final clinical study report for Merck/Schering-Plough’s Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe), and Merck’s Zocor (simvastatin), which were the ...

In 2009, pharmacists filled over 200 million prescriptions for statins, the drug that’s thought to prevent heart attacks and strokes. And, manufacturers of the drug, more commonly known as Zocor, ...

WASHINGTON (Reuters) - Patients on the highest approved dose of the cholesterol-lowering drug Zocor may be at increased risk of muscle injury, U.S. regulators warned on Friday. Made by Merck & Co and ...

June 20, 2006 — -- This Friday, Merck's patent on the cholesterol - lowering drug Zocor will expire. There will now be a generic version of the drug for sale called Simvastatin. Are you taking ...

Zocor buy with visa online Nuclear fractions and cytoplasmic fractions were respectively analyzed by Western blotting for the detection of Nrf2 nuclear translocation Simvastatin increases the nuclear ...

A meta-analysis of 123,940 patients found most muscle pain or weakness is not related to statin therapy, according to a study published Aug. 29 in The Lancet. International researchers conducted a ...

BANGALORE (Reuters) - U.S. health regulators recommended limiting the use of the highest dose of Merck & Co's cholesterol drug Zocor, citing an increased risk of muscle damage. Zocor, also known as ...